Project Updates and Milestones news (page 6)

• 

  2 June 2026

  SOCAR and BCG sign cooperation on Caspian methane reduction

  Joint effort to fast-track methane cuts in Caspian oil and gas operations through projects, research and best-practice exchange, aiming for reductions by 2030.
• 

  2 June 2026

  Iberdrola awarded eight EU Innovation Fund projects for industrial heat electrification

  Eight industrial heat electrification projects will replace fossil heat with electric boilers, require about 240 GWh/year, mobilise 150 MW of renewables and secure ~€50m in aid.
• 

  2 June 2026

  VolagHy and Airbus co-finance Kuopio eSAF feasibility study

  Feasibility and financial modelling launched for a Kuopio flagship plant that aims to scale electro-based sustainable aviation fuel across the Nordics by 2040.
• 

  2 June 2026

  Roche: FDA accepts priority‑review NDA for giredestrant in ER‑positive early‑stage breast cancer

  FDA accepted priority NDA for oral SERD giredestrant as adjuvant in ER‑positive, HER2‑negative stage I–III breast cancer after phase III lidERA showed 30% iDFS risk reduction; PDUFA 30 Nov 2026.
• 

  2 June 2026

  INEOS Energy signs LNG supply deal with Marubeni for Asia deliveries from 2029

  DES LNG supply agreement to deliver into Asian markets, marking the firm's first Pacific Basin deliveries and expanding its diversified global LNG portfolio to meet rising regional demand.
• 

  2 June 2026

  EAS Batteries launches ultra‑high‑power 22 Ah LFP cell using Asahi Kasei Acetolyte

  22 Ah LFP cell using acetonitrile electrolyte achieves 2,550 W/kg continuous, 3,760 W/kg 2s pulse, ~2,400 cycles at 5C/100% DoD; samples in customer evaluation; 46xxx format planned.

• 

  1 June 2026

  Solvay and Viridis LOI for Brazil-to-La Rochelle rare-earth supply

  LOI aims to deliver Brazilian rare-earth feedstock to a French separation plant by 2028, supporting magnet-grade Nd/Pr/Dy/Tb supply and industrial Dy/Tb separation by Sep 2026.
• 

  1 June 2026

  Genentech: FDA accepts NDA for giredestrant after positive Phase III adjuvant results in early ER‑positive breast cancer

  lidERA Phase III: giredestrant reduced invasive recurrence/death by 30% (HR 0.70); 3‑yr iDFS 92.4% vs 89.6%. Priority review; PDUFA Nov 30, 2026; well tolerated in >4,100 pts.
• 

  1 June 2026

  Honeywell names Jill Evanko to board

  Evanko, Duravant CEO with 25+ years in industrial and manufacturing (ex-Chart Industries CEO/CFO), joins as independent director and Audit Committee member; Notre Dame MBA.
• 

  1 June 2026

  Fluor‑JGC JV Wins LNTP for LNG Canada Phase 2 Expansion

  Limited notice to proceed issued to begin early planning and key activities for the proposed Phase 2 expansion at the LNG Canada Kitimat export facility, supporting an FID that would double 14 Mtpa.
• 

  1 June 2026

  Moderna & Merck: 5‑Year Data — Intismeran plus KEYTRUDA Reduces Recurrence in High‑Risk Resected Stage III/IV Melanoma

  5-year Phase 2b follow-up: combination showed 49% RFS reduction (HR 0.51), 59% DMFS reduction (HR 0.411); OS trend (HR 0.471). Safety consistent; increased neoantigen-specific T‑cell clonotypes
• 

  1 June 2026

  bp starts non-associated gas production at ACG

  Commercial NAG started from West Chirag; well tests Qirmaki sands. Est. 4–6 Tcf recoverable; gas sent to Sangachal via existing infrastructure.
• 

  1 June 2026

  Linde 2025 Sustainability Report

  2025: 10% absolute GHG cut vs 2021; 50% electricity from low-carbon/renewables; customers avoided ~98M tCO2e; conserved 1B+ gallons water; diverted 200M lbs waste; supported ~2,100 orgs, 400k people.
• 

  1 June 2026

  Vopak and Gasunie take conditional FID to extend EemsEnergyTerminal

  Conditional FID approved for extension of EemsEnergyTerminal, advancing LNG infrastructure; final FID pending permits. Customer contracts secured for LNG supply 2028–2036.
• 

  1 June 2026

  Roche to present obesity‑portfolio data at ADA 2026

  Phase II data show enicepatide and petrelintide yield meaningful weight loss with good safety/tolerability. Both advance toward Phase III; a Phase II combo trial starts mid‑2026
• 

  1 June 2026

  CATL opens world’s largest energy-storage testbed for real-world validation

  10-ha, RMB3bn Xiamen facility offers open station-level validation across five labs: 35kV/100MVA grid sim, 1kV–500kV HV tests, 20MW combustion, -50–100°C climate chambers, EMC for 40-ft containers
• 

  31 May 2026

  Lilly: Retevmo reduces recurrence/death risk by 83% as adjuvant in early‑stage RET‑fusion NSCLC

  Phase 3 LIBRETTO-432 randomized 151 early-stage RET‑fusion NSCLC patients; at 24‑month follow‑up EFS rates 92% vs 61% (treatment vs placebo). Safety: elevated ALT/AST manageable with dose changes.
• 

  31 May 2026

  Johnson & Johnson PROTEUS Phase 3: Perioperative ERLEADA reduces risk of metastasis or death by 20%

  Perioperative apalutamide + ADT (6 months pre/post-surgery) raised pCR/MRD to 8.9% vs 1%, delayed need for further therapy >6 vs 3.5 years, met dual primary endpoints; safety profile as expected.
• 

  31 May 2026

  Johnson & Johnson: RYBREVANT FASPRO shows durable responses in advanced head and neck cancer

  Phase 1b/2 OrigAMI-4: subcutaneous amivantamab + hyaluronidase achieved 42% ORR (15% CR) in pretreated recurrent/metastatic HNSCC; median DOR not reached (11.8 mo FU); manageable safety.
• 

  29 May 2026

  RWE builds 24.7 MWp solar farm for KRONOS TITAN in Nordenham

  24.7 MWp PV on 20 ha with >38,300 modules, producing ≈22,000 MWh/year under a long-term PPA to supply a significant share of the site's electricity demand.
• 

  29 May 2026

  EU advances carbon removals and carbon farming market

  CRCF Days launched rollout: certification schemes may seek CRCF recognition; Buyers’ Club to aggregate demand; removals and carbon‑farming methodologies near adoption; financing and de‑risking needed
• 

  29 May 2026

  Velocys, Tetracore sign MOU to evaluate modular GTL in Nigeria

  MOU to assess modular Fischer-Tropsch microFTL for Atakobo GTL in Ogun State - convert ~55 MMSCFD (~5,000 BPD) into diesel, Jet-A1 and naphtha to support domestic fuel supply.
• 

  29 May 2026

  Johnson & Johnson: RYBREVANT + LAZCLUZE yields 41‑month median OS in first‑line atypical EGFR‑mutant NSCLC

  CHRYSALIS-2 Phase1/1b (n=49): first-line atypical EGFR‑mutant NSCLC showed ORR 57%; 3‑yr OS 55%, 4‑yr OS 46%; 41% remained on treatment ≥2 years; safety consistent with prior reports.
• 

  29 May 2026

  Petrobras to invest over R$70 billion in Sergipe

  R$70B in Sergipe funds SEAP deep-water (P-81/P-87 FPSOs: 240k bpd, gas processing), 32 wells, 134 km pipeline; R$12.5B decommission 26 shallow platforms; fertilizer restarted (1.8k t/d)
• 

  29 May 2026

  Rompetrol Rafinare Q1 2026: Turnover up 8%, net profit achieved

  Q1: EBITDA $27.5M; March shutdown (700+ tasks) completed; Petromidia processed ~1.2Mt, white product yield 83.76%; domestic fuel share 66%; state contribution $577M
• 

  29 May 2026

  Johnson & Johnson: TECVAYLI improves PFS and OS in second-line multiple myeloma

  Phase 3 MajesTEC‑9: teclistamab cut progression/death risk 71% (HR 0.29) and death 40% (HR 0.60) vs PVd/Kd in early RRMM; higher ≥CR (65.9% vs 16.8%); infections and CRS increased
• 

  29 May 2026

  EU Innovation Fund Net‑Zero Call: 358 applications, €17.5bn requested (6× budget)

  Applicants across 27 countries submitted large/medium/small projects, pilots and cleantech manufacturing for energy‑intensive, carbon management, renewables and storage; results Oct 2026
• 

  29 May 2026

  Merck: FDA Grants Breakthrough Designation to Calderasib (MK‑1084) for First‑Line KRAS G12C‑Mutant Metastatic NSCLC

  Supports calderasib plus pembrolizumab in PD‑L1 ≥1% newly diagnosed metastatic KRAS G12C NSCLC; positive Phase 1 KANDLELIT‑001 data; multiple Phase 3 trials planned; developed with Taiho/Astex
• 

  29 May 2026

  IFF to sell Food Ingredients business to CVC

  Food Ingredients business sold for ~$4.3B (≈10x EBITDA); seller retains ~10% stake; net proceeds ~$3.8B for debt reduction, buybacks and reinvestment; close by end Q2 2027.
• 

  29 May 2026

  AGC verifies AFLAS FFKM fluorine as 100% recycled under UL 2809

  Mass-balance allocation applied to AFLAS FFKM; product offers strong chemical/heat/plasma resistance for semiconductor seals. Part of effort to recycle plant fluorine waste and advance circularity.